Trial Profile
A randomised phase II study evaluating tumour response to Dual inhibition of EGFR signalling using CetUXimab and Erlotinib or dose escalated Cetuximab in patients with chemotherapy refractory KRAS wild-type metastatic colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary) ; Doxycycline; Hydrocortisone
- Indications Colorectal cancer; Erythema
- Focus Biomarker; Therapeutic Use
- Acronyms DUX2
- 18 Jul 2013 Status changed from not yet recruiting to discontinued as reported by Australian New Zealand Clinical Trials Registry.
- 06 Dec 2011 New trial record